(VIANEWS) – MEDISTIM shares fell 10.43% to close at Kr206.00 today, continuing their five-day losing streak and Oslo Bors Benchmark Index_GI’s downward movement from five consecutive gains prior to today. MEDISTIM’s last close was 26.4% below its 52-week high of Kr312.50.
About MEDISTIM
Medistim ASA, established in 1984 in Oslo, Norway, specializes in cardiovascular surgery medical device sales and distribution. Their MiraQ Cardiac and MiraQ Vascular products combine ultrasound imaging and transit time flow measurement in single systems for cardiovascular surgery procedures. Furthermore, Medistim offers various flow and doppler probes for intraoperative use as well. Medistim also distributes third-party medical equipment.
Yearly Analysis
According to available data, MEDISTIM’s stock is currently trading at kr206.00; significantly below its 52-week high of kr312.50 but higher than its low of kr184.80. This indicates a decline in value over the last year but its recent rebound suggests its potential recovery.
MEDISTIM is projected to experience sales growth of 12-14% this year and 9.4 % next year – this indicates an expected rise in its revenue over time.
MEDISTIM’s EBITDA, which measures profitability, stands at 7.97. This indicates that they are producing positive cash flow and are therefore profitable.
Overall, investors may consider MEDISTIM as an attractive investment opportunity based on its projected sales growth and positive EBITDA projections. Before making their decisions however, investors should carefully examine other aspects such as financial statements, industry trends and market conditions of MEDISTIM before making their own judgment call on this company.
Technical Analysis
MEDISTIM Stock Prices Substantial Decrease As Investors RetreatMEDISTIM’s stock has seen significant value erosion recently, falling significantly below both its 50-day moving average of kr257.26 and 200-day moving average of kr251.43. It currently trades at KR126.30; significantly below both figures. This pattern indicates a bearish trend in the market, as investors sell off shares. This can be linked to changes in market sentiment or economic indicators or company-specific news. However, when stock prices fall far below their moving averages it suggests they may continue to drop. Furthermore, with volume at 19828 being 1013.93% higher than its average volume of 1780 it indicates there may be selling pressure in the market that will compound any downward trends that arise in future trading sessions. Furthermore, volatility has fluctuated in recent weeks, with weekly, monthly, and quarterly intraday variation averages being negative 0.43%, negative 0.57%, and positive 2.23% respectively over recent weeks, months, and quarters respectively. However, the highest average volatility was 2.23% last quarter, suggesting that MEDISTIM’s stock has become increasingly risky to investors. According to stochastic oscillator’s classification system for overbought and oversold conditions (>=80), MEDISTIM stock has reached overbought status (>=80). MEDISTIM’s stock has experienced a significant decrease in value, prompting investors to exercise caution when looking at it as an investment option. Due to its bearish trend, high selling pressure, and volatile nature, this may pose more of a risk than usual and investors should carefully evaluate any decisions to purchase this investment before investing.
Quarter Analysis
According to available data, MEDISTIM’s current sales growth stands at 16.7%; an encouraging sign for its performance. Furthermore, forecasted growth estimates for next quarter stand at 5.1% indicating potential continuation of positive sales trends.
At 11.1%, this company’s estimated quarterly growth suggests strong potential in the coming months. Unfortunately, next quarter’s estimates drop 6.7% which may signify some uncertainty or potential slowdown.
Overall, an 11.3% annualized quarterly revenue growth over twelve trailing months should be welcomed by investors as it signals continued success for their investments. When making investment decisions it is vital to take both current and projected growth estimates into consideration when making decisions about investments.
Equity Analysis
According to available data, Medistim’s PE ratio stands at 32.54 and indicates that investors may be paying a premium for its earnings. Meanwhile, Medistim’s return on equity of 31.89% indicates it generates sufficient profit relative to shareholder’s equity.
Income-oriented investors may find the estimated forward annual dividend yield of 1.96% unappealing; however, its next dividend payment date of April 25th 2023 provides potential income streams.
Overall, Medistim appears to be a profitable company with an excellent return on equity. Investors should carefully examine its PE ratio and dividend yield before making any investment decisions.
More news about MEDISTIM (MEDI.OL).
